# Mike Dial

> Mike Dial is a Series B investor at Chugai Venture Fund backing Biotechnology. See 7 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Chugai Venture Fund](https://shizune.co/investors/profile/chugai-venture-fund)
- Location: Boston, United States
- Total investments: 7
- Last investment: Feb 2026
- Lead investor: 29%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/michael-dial-33a3248

Mike Dial is a Series B investor at Chugai Venture Fund in Boston focused on Biotechnology and Pharmaceutical. Mike Dial is based out of Boston, Massachusetts, and is the Managing Director of Chugai Venture Fund and also a Board of Director of Ten63 Therapeutics. Mike previously worked at Hatteras Venture Partners as a General Partner. Mike Dial attended UNC School of Medicine.

## Contacts

5 contacts available for Mike Dial: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/mike-dial-742c?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 57% |
| Pharmaceutical | 3 | 43% |
| Medical | 2 | 29% |
| Health Care | 1 | 14% |
| Life Science | 1 | 14% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 29% |
| Seed | 1 | 14% |
| Series A | 1 | 14% |
| Series C | 1 | 14% |
| Series D | 1 | 14% |

6 stages tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Ten63 Therapeutics | Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI andstate-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable. |  | Venture - Series Unknown | Feb 19, 2026 |  |
| Ribometrix | Ribometrix is a platform therapeutics company that discovers small molecule drugs that target functional 3D RNA structures to treat human diseases. Our scientific offices are located in the newly renovated Biolabs Space in Durham, with offices in Chapel Hill and Boston. | $30M | Series A | Nov 13, 2018 |  |
| Ribometrix | Ribometrix is a platform therapeutics company that discovers small molecule drugs that target functional 3D RNA structures to treat human diseases. Our scientific offices are located in the newly renovated Biolabs Space in Durham, with offices in Chapel Hill and Boston. | $7.5M | Seed | Oct 31, 2017 |  |
| G1 Therapeutics | G1 Therapeutics is a clinical-stage company developing novel cancer therapies. It was founded in 2008 by Drs. Norman Sharpless and Kwok-Kin Wong to capitalize on discoveries made and patented by Dr. Sharpless’ lab at the University of North Carolina at Chapel Hill, and subsequently licensed to G1 Therapeutics. Trilaciclib is an investigationaltherapy designed to improve outcomes for people with cancer who are treated with chemotherapy. G1 is also advancing rintodestrant, a potential best-in-class oral selective estrogen receptor degrader, or SERD, for the treatment of ER+ breast cancer. | $47M | Series C | May 11, 2016 |  |
| G1 Therapeutics | G1 Therapeutics is a clinical-stage company developing novel cancer therapies. It was founded in 2008 by Drs. Norman Sharpless and Kwok-Kin Wong to capitalize on discoveries made and patented by Dr. Sharpless’ lab at the University of North Carolina at Chapel Hill, and subsequently licensed to G1 Therapeutics. Trilaciclib is an investigationaltherapy designed to improve outcomes for people with cancer who are treated with chemotherapy. G1 is also advancing rintodestrant, a potential best-in-class oral selective estrogen receptor degrader, or SERD, for the treatment of ER+ breast cancer. | $33M | Series B | Feb 05, 2015 |  |
| Viamet Pharmaceuticals | Viamet Pharmaceuticals discovers and develops "best-in-class" inhibitors of validated metalloenzymes via an innovative and proprietary metal-binding approach, their Metallophileâ„¢ Technology. Viamet's disruptive Metallophileâ„¢ technology is based on their world-class expertise in bioinorganic chemistry and metalloenzymes and allowsthem to identify validated targets with high therapeutic and commercial potential; leverage existing metalloenzyme inhibitors as the basis for Viamet's best-in-class analogs; and rapidly and cost-effectively generate best-in-class, patentable, small molecule compounds by optimizing the metal-binding component of existing inhibitors. | $60M | Series D | Oct 21, 2014 |  |
| Viamet Pharmaceuticals | Viamet Pharmaceuticals discovers and develops "best-in-class" inhibitors of validated metalloenzymes via an innovative and proprietary metal-binding approach, their Metallophileâ„¢ Technology. Viamet's disruptive Metallophileâ„¢ technology is based on their world-class expertise in bioinorganic chemistry and metalloenzymes and allowsthem to identify validated targets with high therapeutic and commercial potential; leverage existing metalloenzyme inhibitors as the basis for Viamet's best-in-class analogs; and rapidly and cost-effectively generate best-in-class, patentable, small molecule compounds by optimizing the metal-binding component of existing inhibitors. | $25M | Series B | Jul 07, 2009 |  |

7 of 7 investments shown.

## Co-investors
- [AbbVie](https://shizune.co/investors/profile/abbvie) — VC Fund, 2 deals together
- [AbbVie Biotech Ventures](https://shizune.co/investors/profile/abbvie-biotech-ventures) — VC Fund, 2 deals together
- [Astellas Venture Management](https://shizune.co/investors/profile/astellas-venture-management) — VC Fund, 2 deals together
- [Dementia Discovery Fund](https://shizune.co/investors/profile/dementia-discovery) — VC Fund, 2 deals together
- Eshelman Ventures — VC Fund, 2 deals together
- [Intersouth Partners](https://shizune.co/investors/profile/intersouth-partners) — VC Fund, 2 deals together

## About Chugai Venture Fund

VC Fund · Boston, United States

Chugai Venture Fund is a pioneering investment firm that promotes innovation and creates revolutionary improvements in the life sciences industry.

2 contacts available at Chugai Venture Fund.

| Name | Title | Profile |
| --- | --- | --- |
| John Gustofson | Founder & President | https://shizune.co/investors/profile/john-gustofson |
| Mike Dial | Managing Director | — |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Mike Dial invest in?

Mike Dial invests primarily in Biotechnology, Pharmaceutical and Medical startups, most often at Series B and Seed stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Mike Dial?

Public channels for Mike Dial include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Mike Dial last invest?

The most recent investment recorded for Mike Dial closed in Feb 2026. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co